hotspot -WSS

hotspot

author：hotspot 2025-09-29 12:30:17 - browse：45

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： What to expect at HLTH 2023, the health care industry conference

entertainment

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Liquid biopsy for lung cancer is launched by Delfi

Hospitals owned by private equity see complications spike 25%

CRISPR gene editing developments we’re watching in 2024

Senate panel eyes new effort on drug shortages

How to keep neuroscience’s past racism from being its future

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Drug repurposing or repositioning? The language matters

What STAT readers think about the FDA and patient advocacy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Grail spinoff by Illumina should end disastrous merger attempt

In age of alternative facts, a scholarly course on calling out crap

FDA authorizes Novavax’s updated Covid

In age of alternative facts, a scholarly course on calling out crap

Virtual care provider acquires bankrupt Pear's prescription apps

BioMarin wins approval for gene therapy to treat hemophilia A

Grail spinoff by Illumina should end disastrous merger attempt

leisure time

VC firm General Catalyst wants to buy a health system

Analysis of telehealth claims data suggest service duplication

Phenylephrine and the overlooked value of the placebo effect

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

What to expect at HLTH 2023, the health care industry conference

focus

entertainment

hotspot

leisure time